Skip to main content
Clinical Trials/NCT03534609
NCT03534609
Completed
Not Applicable

Exploratory Evaluation of the Lutronic Genius System for Treatment of the Neck

LUTRONIC Corporation1 site in 1 country18 target enrollmentStarted: March 27, 2018Last updated:

Overview

Phase
Not Applicable
Status
Completed
Enrollment
18
Locations
1
Primary Endpoint
Masked qualitative assessment of improvement

Overview

Brief Summary

The Genius system is substantially equivalent to the Infini device (K121481). The study is a prospective, multi-site, non-randomized study of up to 30 treated subjects presenting for treatment of mild to moderate lines, wrinkles, textural concerns, and/or skin laxity of the neck.

Detailed Description

At enrollment, standardized baseline/pretreatment 2D and 3D images will be obtained from each subject. Study subjects will receive three neck treatments completed 30 days apart. Subjects will be contacted via a phone call 3 days following each treatment to assess for adverse events and expected treatment effects. Effectiveness assessments will occur prior to Treatments #2 and #3, and a follow-up visit will be completed at 90 days following Treatment #3. Each assessment visit will include efficacy, adverse events, and expected treatment effects assessments, and post-treatment 2D and 3D digital images will be captured.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Male or female, age 18 years and older.
  • Subject in good health.
  • Fitzpatrick Skin Type I to VI.
  • Mild to moderate lines, wrinkles, textural concerns, and/or skin laxity of the neck.
  • Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period.
  • Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.
  • Post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study.
  • Absence of physical or psychological conditions unacceptable to the investigator.
  • Willingness and ability to provide written consent for study-required photography and adherence to photography procedures (i.e., removal of jewelry and makeup).
  • Willingness and ability to provide written informed consent and HIPAA authorization prior to performance of any study-related procedure.

Exclusion Criteria

  • Presence of an active skin condition or infection in the treatment area such as sores, Psoriasis, eczema, rash, severe active inflammatory acne or oral herpes simplex breakout.
  • History of skin disorders, keloid scarring, and/or abnormal wound healing.
  • Open wounds or lesions in the area(s) to be treated.
  • Inability to understand the protocol or to give informed consent.
  • History of chronic drug or alcohol abuse.
  • History of vascular disease.
  • History of bleeding disorders.
  • BMI equal to or greater than
  • Subjects who are pregnant, nursing, or anticipate a pregnancy during the length of the trial.
  • Subjects with current skin cancer or other malignant disease including pre-malignant moles.

Outcomes

Primary Outcomes

Masked qualitative assessment of improvement

Time Frame: From baseline to 90 days following the last treatment

An assessment of paired pre- and post-treatment photographs will be conducted by blinded assessors evaluating for improvement in neck appearance from pre- to post-treatment. The assessors choose the photo they believe to be the post-treatment photo, i.e., Left photo or Right photo.

Secondary Outcomes

  • Subject aesthetic improvement(From baseline to Days 90 following the last study treatment.)
  • Clinician aesthetic improvement(From baseline to Days 90 following the last study treatment.)
  • Patient Satisfaction(From baseline to 90 days following the last study treatment)
  • Treatment-related pain(For the duration of each study treatment which typically can last up to approximately 90 minutes.)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials